Board MeetingOutcome of Board Meeting
Valiant Laboratories' board has approved its Q3 FY26 consolidated financial results.
Valiant Laboratories LimitedVALIANTLAB · Filed with the exchange
Revenue from operations stood at ₹5.25 Cr, while the company reported a net loss of ₹7.06 Cr.
EPS was ₹(1.30).
No comments yet. Be the first.